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Background/Objectives. To evaluate the efficacy of switching to monthly ranibizumab in neovascular age-related macular de-
generation (nAMD) showing an insufficient response to bimonthly aflibercept. Subjects/Methods. A total of 13 nAMD eyes
showing an insufficient treatment response to three successive aflibercept injections were enrolled through a retrospective chart
review. After switching, three consecutive monthly intravitreal ranibizumab injections were performed. *e main outcome
measurements included the best-corrected visual acuity (BCVA), central retinal thickness (CRT), presence of intraretinal fluid
(IRF), and subretinal fluid (SRF) using optical coherence tomography (OCT) and were measured every month. Results. CRTand
logMAR VA were 349.62± 223.51 μm and 0.50± 0.23 at the baseline and 274.69± 148.77 μm and 0.46± 0.24, 311.54± 192.90 μm
and 0.45± 0.20 at 1 month after the first and third ranibizumab injections, respectively. *e CRT decrease during three
ranibizumab injections was statistically significant (38.08± 69.52 μm, p � 0.033). Change in VA was not statistically significant.
*e percentage of eyes with SRF was 100% at baseline and 53.8%, 76.9%, and 69.2% one month after each ranibizumab injections.
*e percentage of eyes with IRF was 38.5% at baseline and 23.1%, 23.1%, and 15.4%, respectively, after switching. Conclusion.
Switching to monthly ranibizumab in nAMD showing an insufficient response to bimonthly aflibercept led to immediate
anatomical improvement. It can be considered in countries where the healthcare insurance system limits the minimum injection
interval of aflibercept.
1. Introduction
Age-related macular degeneration (AMD) is one of the
significant causes of blindness worldwide. *e gold standard
treatment for neovascular age-related macular degeneration
(nAMD) is an intravitreal antivascular endothelial growth
factor (VEGF) therapy. Intravitreal anti-VEGF medications
bevacizumab and ranibizumab are first introduced and
recognized for improving visual and anatomical outcomes in
patients with nAMD [1, 2]. Aflibercept was introduced
several years later. *e calculated duration of the effect of a
single intravitreal injection of 2mg aflibercept was reported
to be 48–83 days due to its higher affinity for VEGF and
longer half-life compared with both bevacizumab and
ranibizumab [3, 4]. Monthly or bimonthly intravitreal
aflibercept injections demonstrated similar therapeutic ef-
fects as monthly intravitreal ranibizumab injections [5].
Based on these reports, the health insurance system in many
countries, including Korea, sets a minimum intravitreal
injection interval of 2 months for aflibercept.
Hindawi
Journal of Ophthalmology
Volume 2021, Article ID 5547686, 8 pages
https://doi.org/10.1155/2021/5547686
However, in some patients, the intravitreal injection
effect of aflibercept is not maintained for 2 months. Fauser
et al. [6] reported that the intraocular VEGF concentrations
were suppressed below the lower limit of quantification
(4 pg/mL) after intravitreal aflibercept injections for about
10 weeks on average. However, this study showed that the
VEGF suppression effect by aflibercept could be shorter
than two months in some patients. *e real-world data of
treatment and extend (T&E) treatment for nAMD using
aflibercept also shows a subgroup of patients who need
treatment at intervals shorter than two months [7]. As a
result, more frequent anti-VEGF treatment is necessary for
these patient groups. In South Korea, where the solitary
national health insurance system has limited the minimum
interval of aflibercept treatment to two months, switching
to monthly ranibizumab treatment or additional bev-
acizumab treatment might be required for these patients. In
most other countries, the health insurance system is not as
simple as that of Korea, and the policies of several private
health insurance companies are diverse and constantly
changing. However, previous studies using real-world data
confirmed that, in many countries, the minimum dosing
interval of aflibercept is limited to 2 months. Europe, es-
pecially the United Kingdom, is a representative example
(SAFARI study) [8].
Although there have been several reports about the
therapeutic effect of switching from ranibizumab to afli-
bercept [9–14] or switch-back to ranibizumab [15, 16], data
on switching from bimonthly aflibercept to monthly rani-
bizumab are sparse. Although most previous studies have
reported favorable outcomes after switching from ranibi-
zumab to aflibercept, it is possible that the disease’s natural
course and “anti-VEGF resistance” were involved in addi-
tion to the drug’s effects.
*is report evaluates the switching effect in terms of
“anti-VEGF resistance” and the efficacy of monthly rani-
bizumab treatment in patients with nAMD showing an
insufficient treatment response to bimonthly aflibercept; we
investigated the anatomical and functional outcomes after
switching from bimonthly aflibercept to monthly
ranibizumab.
2. Materials and Methods
2.1. Participants. Eligible patients were ≥50 years of age with
nAMD who visited Seoul National University Bundang
Hospital and Severance Eye Hospital. *e patients had a
macula-involving active choroidal neovascularization lesion
secondary to typical AMD or polypoidal choroidal vasculop-
athy (PCV) in the study eye. Insufficient responders to afli-
bercept were defined as those with subretinal fluid remaining
or increasing despite more than three successive injections of
aflibercept (2.0mg/0.05ml) at 1- or 2-month intervals, and the
last injection was performed bimonthly before switching to
ranibizumab. As a result, eligible patients who received three
consecutive successive injections of aflibercept injections im-
mediately before switching were enrolled, regardless of the
treatment history (other anti-VEGF injections or photody-
namic therapy (PDT)). In all enrolled patients, dry-up of SRF
was observed at least once after initiation of anti-VEGF
treatment for nAMD, and the SRF recurred while maintaining
bimonthly aflibercept treatment.
2.2. Study Design. *ree consecutive ranibizumab (0.5mg/
0.05ml) doses were administered by monthly intravitreal
injection at “baseline” (the day determined to “switch,” 2
months after the last aflibercept injection), “1 month”
(30–37 days after first ranibizumab injection), and “2
months” (30–37 days after second ranibizumab injection).
Visual acuity (VA) and optical coherence tomography
(OCT) measurements were conducted at baseline, 1 month,
2 months, and 3 months (30–37 days after the third rani-
bizumab injection; Figure 1). From 3 months after switching
(1 month after third ranibizumab injection), one of the
following treatment methods was applied to each patient
according to the monthly ranibizumab treatment response:
maintaining monthly ranibizumab treatment, ranibizumab
treatment with an extended injection interval, or reswitching
to an aflibercept-based treatment (bimonthly aflibercept or
monthly aflibercept or monthly cross-injection with
bevacizumab).
2.3. Efficacy Assessments. *e main outcome measurements
(primary efficacy variables) included VA and central retinal
thickness (CRT) using spectral-domain optical coherence
tomography (SD-OCT, Spectralis OCT; Heidelberg Engi-
neering, Heidelberg, Germany). *e secondary efficacy
variables included the proportion of eyes with remnant or
recurrent intraretinal fluid (IRF) and subretinal fluid (SRF)
to confirm the patient’s retinal morphology before and after
switching.
2.4. Statistical Analysis. To evaluate the anatomical and
functional efficacy of three monthly ranibizumab treat-
ments, CRT and VA of “1 month” and “3 months” were
compared to “baseline.” Due to the small number of patients
and nonnormal distribution of the observed data for the
CRT and VA, the Wilcoxon signed-rank test was used.
Statistical significance was defined as a p value< 0.05. All
statistical analyses were performed using SPSS version 24.0
(SPSS Inc., Chicago, USA).
3. Results
We identified 13 eyes from 13 patients with neovascular
AMD (including 6 eyes of PCV) showing an insufficient
treatment response to aflibercept treatment. *ese patients
showed remaining or increasing SRF during three consec-
utive successive aflibercept intravitreal injections before
switching and received three consecutive monthly ranibi-
zumab intravitreal injections. Of the 13 eyes, three cases
were included in which the interval between the first 2 out of
3 consecutive aflibercept injections was 1 month. *e de-
mographics and treatment history of the enrolled patients
are summarized in Table 1.
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3.1. Primary Efficacy Variables. *e average CRTs at
baseline and 1 month after each ranibizumab injection
were 349.62 ±223.51 μm, 274.69 ± 148.77μm, 330.62±
240.02 μm, and 311.54 ± 200.77 μm, respectively. *e
differences between the average CRT at baseline and av-
erage CRT at 1 month and 3 months (1 month after third
ranibizumab injection) after the switching were statisti-
cally significant (74.92 ± 88.74 μm, p � 0.002 and
38.08 ± 69.52 μm, p � 0.033, Wilcoxon signed-rank test).
Figure 2 shows changes in individual and in average CRT
and average BCVA. *e average CRT most remarkably
decreased 1 month after the switch and slightly increased
for the second month. *e differences in CRT between 1
and 2 months and 2 and 3 months were not statistically
significant (p � 0.120 and 0.074, respectively). *e treat-
ment response based on CRT worsened in two patients
three months after the switching, and transient aggrava-
tion after the second ranibizumab injection was observed
in eight patients.
*e average LogMAR VA at baseline and 1, 2, and 3
months were 0.50± 0.23, 0.46± 0.24, 0.49± 0.25, and
0.45± 0.20, respectively. *e average VA tended to improve
after switching, but the average VA difference between
baseline and 1 month after the third ranibizumab injection
(0.07± 0.12) was not statistically significant (p � 0.114,
Wilcoxon signed-rank test) (Figure 2).
3.2. Secondary Efficacy Variables. SRF was observed in the
baseline OCT in all enrolled eyes. At “1 month” (1 month
after the 1st ranibizumab injection), the proportion of eyes
with SRF decreased dramatically. In 53.8% of the enrolled
eyes, SRF was completely absorbed, and 46.2% of the en-
rolled eyes showed residual SRF. However, despite con-
tinuing monthly ranibizumab injection, the tendency of SRF
recurrence was observed at 1 month after second and third
ranibizumab treatment. *e height of the recurrent SRF was
not higher than that of the baseline (Figures 3 and 4). Re-
sidual IRF was observed in 38.5% of the enrolled eye at
baseline. *e proportion of eyes with residual IRF gradually
decreased to 15.4% at 1 month after the third ranibizumab
injection.
3.3. Long-Term Maintenance of Treatment after Switching.
*e long-term efficacy was assessed in 12 eyes that had been
followed up for 1 year after switching. Among the 12 eyes, 6
eyes (50%) maintained ranibizumab treatment for 1 year,
and the remaining 6 (50%) were reswitched to aflibercept-
based treatment due to an insufficient response to monthly
ranibizumab or patients’ unwillingness to maintain monthly
treatment. Of the 6 eyes treated with ranibizumab, 4
maintained monthly ranibizumab for 1 year and 2 extended
the injection interval. *e remaining six eyes were changed
to an aflibercept-based regimen during the 1 year follow-up
period. At the last visit, four of themwere cross-injected with
aflibercept and bevacizumab every month. One eye main-
tained bimonthly aflibercept, and the other maintained
monthly aflibercept. *e average number of monthly
ranibizumab maintenance for 1 year after switching was
8.67± 2.90 (Figure 5).
4. Discussion
Switching to monthly ranibizumab with three consecutive
injections in patients with nAMD showing an insufficient
response to bimonthly aflibercept led to immediate ana-
tomical improvement, especially in the first month after
switching. Twomonths after switching, CRTand SRF tended








Figure 1: Flow diagram showing the schedule of intravitreal injections and OCTmeasurements of the enrolled eyes with nAMD. CRT,
central retinal thickness; IRF, intraretinal fluid; SRF, subretinal fluid.
Table 1: Clinical and demographic characteristics of included
patients with neovascular age-related macular degeneration
showing an insufficient response to bimonthly aflibercept.
Characteristic Mean or number
Male-to-female ratio, no. (%) 11 : 2(84.6% :15.4%)
Mean age at baseline (y) 72.77± 8.27
Type of nAMD, typical nAMD : PCV (%) 7 : 6 (53.8% : 46.2%)





Previous PDT (%) 2 (15.4%)
Baseline central retinal thickness, μm 349.62± 223.51
Baseline best-corrected visual acuity,
logMAR 0.50± 0.23
nAMD, neovascular age-related macular degeneration; PCV, polypoidal
choroidal vasculopathy; R, right; L, left; A, aflibercept; B, bevacizumab;
PDT, photodynamic therapy.
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to increase slightly again, indicating the switching effect’s
decay after repeated injections.
*ere have been several reports comparing the thera-
peutic effects of ranibizumab and aflibercept in treatment-
naı̈ve patients with nAMD. In these studies, equivalent
therapeutic effects (in terms of functional and morphologic
outcomes) and a similar injection burden were observed
between ranibizumab and aflibercept [17–19]. It is also well
known that monthly or bimonthly intravitreal aflibercept
injections demonstrated similar therapeutic effects as
monthly intravitreal ranibizumab injections [5]. In PCV,
aflibercept treatment was more effective than ranibizumab
for polyp regression [19].
Apart from comparing anti-VEGF agents in patients
with treatment-näıve nAMD, there have been studies related
to the treatment response after anti-VEGF agent switching.
A minority of patients with nAMD experience suboptimal
treatment response to continued therapy with the same anti-
VEGF agent (anti-VEGF resistance) [20–23]. Since afli-
bercept was introduced a few years later than ranibizumab
and showed a higher affinity for VEGF, there have been
many reports about the therapeutic effects of switching from
ranibizumab to aflibercept [9–14]. Bakall et al. [10] and
Grewal et al. [11] reported anatomical improvement after
switching to aflibercept in patients with nAMD resistance to
other anti-VEGF agents, bevacizumab and ranibizumab.
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Figure 2: Changes in central retinal thickness (CRT) and visual acuity (VA) after switching from bimonthly aflibercept to monthly
ranibizumab. *e figures on the top show the change in average central retinal thickness (CRT) and best-corrected visual acuity (BCVA).
*e bottom figure shows the change in CRT in individual patients.
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However, potential factors explaining this favorable out-
come after switching include tachyphylaxis, the natural
course of the disease, and injection pattern, as well as the
difference in the anti-VEGF agent itself. One of enrolled
patients visited the clinic one month after the last aflibercept
treatment and showed a favorable anatomical outcome 1
month before “switching,” which means that not only the
drug itself but also the injection interval affects the thera-
peutic effect of anti-VEGF agents in nAMD (Figure 6).
Few studies have been conducted on the therapeutic
effects of reverse switching from aflibercept to ranibizumab.
*e therapeutic effect of switching back to bevacizumab or
ranibizumab for recurrent neovascular activity with afli-
bercept in nAMD was reported to be initially effective [15].
Recently, Gale et al. [8] suggested that patients with nAMD
who have shown a suboptimal response to aflibercept may
benefit from switching to ranibizumab. *is study con-



































Case 1 Case 2 Case 3
Figure 4: OCT findings of the typical cases showing a short-term anatomical good response after “switching” to monthly ranibizumab. One
month after the first intravitreal ranibizumab injection, subretinal fluid (SRF) was dramatically decreased, and in 75%, it was completely
absorbed. In 33.3%, no SRF recurred during 3 months after switching, as in case 1. Despite the consecutive monthly ranibizumab treatment,
SRF recurrence was observed after the second intravitreal ranibizumab injection, as in cases 2 and 3. However, after 3 consecutive monthly
ranibizumab injections, the height of the recurrent SRF was less than that of the baseline, and the final average CRT shows a statistically
significant decrease compared to the baseline.
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led to a significant improvement in CRT, with approxi-
mately 60% experiencing stabilized or improved best-cor-
rected visual acuity (BCVA), although this was
counterbalanced by a large minority (38%) who lost ≥1
letter. *e most remarkable improvement in clinical out-
comes was observed during the initial monthly treatment
period.
Our findings concur with these previous reports and
suggest that the favorable treatment outcome of switching
from bimonthly aflibercept to monthly ranibizumab might
be related to anti-VEGF resistance. In addition, in our study,
a group of patients had BCVA improved, and the change in
average BCVA was not statistically significant but showed a
tendency to improve after 3 monthly injections of ranibi-
zumab compared to baseline. According to many previous
studies about nAMD and visual outcomes, IRF had a much
greater negative impact on the BCVA than SRF [24], while
the presence of subfoveal SRF had little impact on mean
visual acuity, and those with persistent SRF also seemed to
maintain their vision in the long-term [25, 26]. Although the
thickness of the retina gradually increased from 1 month
after switching, it is possible that the final BCVA, 3 months
after the switching point, improved due to the gradual
absorption of IRF.
*e results of “Long-term maintenance of treatment
after switching” show that in 50%, the treatment results of
ranibizumab were satisfactory, and the other 50% was
reswitched due to the decay in the treatment response or the
patient could not maintain the monthly injections. *ere-
fore, although the short-term effect of switching to monthly
ranibizumab showed a favorable response in the refractory
cases, the efficacy tended to reduce gradually, and the long-
term maintenance of monthly ranibizumab treatment might





Cross-injection using Aflibercept and Bevacizumab
Re-switch to Aflibercept Maintain Ranibizumab
Figure 5: Treatment patterns 1 year after switching.
(a) (b)
(c) (d)
Figure 6: Treatment response 1 month after last aflibercept injection (1 month before “switching” to ranibizumab). (a)*e OCT findings at
the time of the last aflibercept injection. (b)*eOCT findings 1 month after the last aflibercept injection. (c)*eOCT findings at the time of
the first ranibizumab injection after “switching.” (d) *e OCT finding 1 month after the first ranibizumab injection. (b) shows a favorable
anatomical outcome 1 month after the aflibercept injection, which means that not only the drug itself but also the injection interval affects
the therapeutic effect of anti-VEGF agents in nAMD.
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As many new anti-VEGF agents with longer half-lives are
continuously being developed, it is important to elucidate the
differences in therapeutic effects between different anti-VEGF
agents. Because new anti-VEGF agents can be injected not
only to treatment-näıve patients but also to patients treated
with existing agents, studies about the clinical effectiveness of
anti-VEGF resistance and the switching effect between var-
ious anti-VEGF agents should be conducted. Monthly afli-
bercept treatment and combination of aflibercept and
ranibizumab or bevacizumab can be appropriate treatment
options for some patients. In addition, a shift to new anti-
VEGF agents, such as brolucizumab, which are expected to be
more effective in nAMD refractory to conventional anti-
VEGF agents, can be an alternative option [27].
*e effectiveness of switching can be evaluated by CRT
changes in the short-term and the reswitching rate in the
long-term. In order to determine the characteristics of pa-
tients with poor treatment response or anti-VEGF resistance,
we evaluated the age, subtype of nAMD, and the type or total
number of anti-VEGF injections, especially previous rani-
bizumab injections. However, we observed no significant
correlations. Furthermore, well-designed prospective or
comparative studies are warranted to identify the long-term
effect of switching, the duration of single anti-VEGF agent
treatment before anti-VEGF resistance, and the selection of
ideal anti-VEGF agents. In addition, a unified criterion of
treatment failure for a specific anti-VEGF agent that can be
used as the basis for regimen change should be established.
*is study has several limitations. First, it is a retrospective,
noncomparative case series that included a small number of
cases. Moreover, there was no comparative data with monthly
aflibercept treatment because of the Korean National Health
Insurance System’s restriction. *erefore, it is impossible to
determine whether switching is due to anti-VEGF agents’
change or injection schedules. We enrolled patients with
nAMD refractory to current aflibercept treatment regardless of
the treatment history (anti-VEGF agents, number of intra-
vitreal anti-VEGF injections, PDT). Nevertheless, these pa-
tients can better represent patients with refractory nAMD in
the real world. We closely followed the retinal morphology
based on OCTat each visit. As a result, although the number of
enrolled patients was not large and the treatment history was
heterogeneous, the short-term treatment effect of switching to
monthly ranibizumab was confirmed in enrolled patients.
5. Conclusion
In conclusion, monthly ranibizumab treatment might be an
effective treatment option for patients with nAMD showing
insufficient bimonthly aflibercept treatment. It should be
more effective and useful in many countries, including Korea,
where the national or private health insurance system limits
the minimum interval of aflibercept injections as twomonths.
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